Oral mucosal organoids as a potential platform for personalized cancer therapy

Else Driehuis; Sigrid Kolders; Sacha Spelier; Kadi Lohmussaar; Stefan M Willems; Lot A Devriese; Remco de Bree; Emma J de Ruiter; Jeroen Korving; Harry Begthel; Johan H Van Es; Veerle Geurts; Gui-Wei He; Richard H van Jaarsveld; Rurika Oka; Mauro J Muraro; Judith Vivie; Maurice M J M Zandvliet; Antoni P A Hendrickx; Nino Iakobachvili; Priya Sridevi; Onno Kranenburg; Ruben van Boxtel; Geert J P L Kops; David A Tuveson; Peter J Peters; Alexander van Oudenaarden; Hans Clevers

doi:10.1158/2159-8290.CD-18-1522

Oral mucosal organoids as a potential platform for personalized cancer therapy

Else Driehuis, Sigrid Kolders, Sacha Spelier, Kadi Lohmussaar, Stefan M Willems, Lot A Devriese, Remco de Bree, Emma J de Ruiter, Jeroen Korving, Harry Begthel, Johan H Van Es, Veerle Geurts, Gui-Wei He, Richard H van Jaarsveld, Rurika Oka, Mauro J Muraro, Judith Vivie, Maurice M J M Zandvliet, Antoni P A Hendrickx, Nino IakobachviliPriya Sridevi, Onno Kranenburg, Ruben van Boxtel, Geert J P L Kops, David A Tuveson, Peter J Peters, Alexander van Oudenaarden, Hans Clevers

Hubrecht Institute

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

241 Citations (Scopus)

Abstract

Previous studies have described that tumor organoids can capture the diversity of defined human carcinoma types. Here, we describe conditions for long-term culture of human mucosal organoids. Using this protocol, a panel of 31 head and neck squamous cell carcinoma (HNSCC)-derived organoid lines was established. This panel recapitulates genetic and molecular characteristics previously described for HNSCC. Organoids retain their tumorigenic potential upon xenotransplantation. We observe differential responses to a panel of drugs including cisplatin, carboplatin, cetuximab and radiotherapy in vitro. Drug screens reveals selective sensitivity to targeted drugs that are not normally used in the treatment of HNSCC patients. These observations may inspire a personalized approach to the management of HNSCC and expand the repertoire of HNSCC drugs.

Original language	English
Journal	Cancer Discovery
Early online date	03 May 2019
DOIs	https://doi.org/10.1158/2159-8290.CD-18-1522
Publication status	Published - Jul 2019

Access to Document

10.1158/2159-8290.CD-18-1522

Cite this

Driehuis, E., Kolders, S., Spelier, S., Lohmussaar, K., Willems, S. M., Devriese, L. A., de Bree, R., de Ruiter, E. J., Korving, J., Begthel, H., Van Es, J. H., Geurts, V., He, G.-W., van Jaarsveld, R. H., Oka, R., Muraro, M. J., Vivie, J., Zandvliet, M. M. J. M., Hendrickx, A. P. A., ... Clevers, H. (2019). Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-18-1522

@article{060c8b9fd07b47c982d023a89166aa2b,

title = "Oral mucosal organoids as a potential platform for personalized cancer therapy",

abstract = "Previous studies have described that tumor organoids can capture the diversity of defined human carcinoma types. Here, we describe conditions for long-term culture of human mucosal organoids. Using this protocol, a panel of 31 head and neck squamous cell carcinoma (HNSCC)-derived organoid lines was established. This panel recapitulates genetic and molecular characteristics previously described for HNSCC. Organoids retain their tumorigenic potential upon xenotransplantation. We observe differential responses to a panel of drugs including cisplatin, carboplatin, cetuximab and radiotherapy in vitro. Drug screens reveals selective sensitivity to targeted drugs that are not normally used in the treatment of HNSCC patients. These observations may inspire a personalized approach to the management of HNSCC and expand the repertoire of HNSCC drugs.",

author = "Else Driehuis and Sigrid Kolders and Sacha Spelier and Kadi Lohmussaar and Willems, {Stefan M} and Devriese, {Lot A} and {de Bree}, Remco and {de Ruiter}, {Emma J} and Jeroen Korving and Harry Begthel and {Van Es}, {Johan H} and Veerle Geurts and Gui-Wei He and {van Jaarsveld}, {Richard H} and Rurika Oka and Muraro, {Mauro J} and Judith Vivie and Zandvliet, {Maurice M J M} and Hendrickx, {Antoni P A} and Nino Iakobachvili and Priya Sridevi and Onno Kranenburg and {van Boxtel}, Ruben and Kops, {Geert J P L} and Tuveson, {David A} and Peters, {Peter J} and {van Oudenaarden}, Alexander and Hans Clevers",

note = "Copyright {\textcopyright}2019, American Association for Cancer Research.",

year = "2019",

month = jul,

doi = "10.1158/2159-8290.CD-18-1522",

language = "English",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

}

Driehuis, E, Kolders, S, Spelier, S, Lohmussaar, K, Willems, SM, Devriese, LA, de Bree, R, de Ruiter, EJ, Korving, J, Begthel, H, Van Es, JH, Geurts, V, He, G-W, van Jaarsveld, RH, Oka, R, Muraro, MJ, Vivie, J, Zandvliet, MMJM, Hendrickx, APA, Iakobachvili, N, Sridevi, P, Kranenburg, O, van Boxtel, R, Kops, GJPL, Tuveson, DA, Peters, PJ, van Oudenaarden, A & Clevers, H 2019, 'Oral mucosal organoids as a potential platform for personalized cancer therapy', Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-18-1522

TY - JOUR

T1 - Oral mucosal organoids as a potential platform for personalized cancer therapy

AU - Driehuis, Else

AU - Kolders, Sigrid

AU - Spelier, Sacha

AU - Lohmussaar, Kadi

AU - Willems, Stefan M

AU - Devriese, Lot A

AU - de Bree, Remco

AU - de Ruiter, Emma J

AU - Korving, Jeroen

AU - Begthel, Harry

AU - Van Es, Johan H

AU - Geurts, Veerle

AU - He, Gui-Wei

AU - van Jaarsveld, Richard H

AU - Oka, Rurika

AU - Muraro, Mauro J

AU - Vivie, Judith

AU - Zandvliet, Maurice M J M

AU - Hendrickx, Antoni P A

AU - Iakobachvili, Nino

AU - Sridevi, Priya

AU - Kranenburg, Onno

AU - van Boxtel, Ruben

AU - Kops, Geert J P L

AU - Tuveson, David A

AU - Peters, Peter J

AU - van Oudenaarden, Alexander

AU - Clevers, Hans

PY - 2019/7

Y1 - 2019/7

N2 - Previous studies have described that tumor organoids can capture the diversity of defined human carcinoma types. Here, we describe conditions for long-term culture of human mucosal organoids. Using this protocol, a panel of 31 head and neck squamous cell carcinoma (HNSCC)-derived organoid lines was established. This panel recapitulates genetic and molecular characteristics previously described for HNSCC. Organoids retain their tumorigenic potential upon xenotransplantation. We observe differential responses to a panel of drugs including cisplatin, carboplatin, cetuximab and radiotherapy in vitro. Drug screens reveals selective sensitivity to targeted drugs that are not normally used in the treatment of HNSCC patients. These observations may inspire a personalized approach to the management of HNSCC and expand the repertoire of HNSCC drugs.

AB - Previous studies have described that tumor organoids can capture the diversity of defined human carcinoma types. Here, we describe conditions for long-term culture of human mucosal organoids. Using this protocol, a panel of 31 head and neck squamous cell carcinoma (HNSCC)-derived organoid lines was established. This panel recapitulates genetic and molecular characteristics previously described for HNSCC. Organoids retain their tumorigenic potential upon xenotransplantation. We observe differential responses to a panel of drugs including cisplatin, carboplatin, cetuximab and radiotherapy in vitro. Drug screens reveals selective sensitivity to targeted drugs that are not normally used in the treatment of HNSCC patients. These observations may inspire a personalized approach to the management of HNSCC and expand the repertoire of HNSCC drugs.

U2 - 10.1158/2159-8290.CD-18-1522

DO - 10.1158/2159-8290.CD-18-1522

M3 - Article

C2 - 31053628

SN - 2159-8274

JO - Cancer Discovery

JF - Cancer Discovery

ER -

Oral mucosal organoids as a potential platform for personalized cancer therapy

Abstract

Access to Document

Fingerprint

Cite this